Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Diagnostic Procedure > Diagnosis, Oral

Diagnosis, Oral

Oral diagnosis is the process of identifying and evaluating conditions affecting the mouth, teeth, and associated structures.
This field encompasses a range of techniques and technologies to assess oral health, detect abnormalities, and guide treatment decisions.
Accurate oral diagnosis is crucial for maintaining optimal oral function, preventing complications, and improving patient outcomes.
PubCompare.ai revolutionizes oral diagnosis research by helping users locate the best protocols from literature, pre-prints, and patents.
Its AI-driven comparisons identify the optimum protocols and products, streamlining your research reproducibility and taking your oral diagnosis studies to new highs.

Most cited protocols related to «Diagnosis, Oral»

1
Assessing Dental Health Literacy in Adult Patients
This 84-item dental/medical health literacy word list was provided to a sample of 200 adult patients seeking treatment for the first time at the UCLA School of Dentistry Oral Diagnosis Clinic between January 2005 and June 2006 following approval of the study protocol by the UCLA institutional review board. Potential participants were screened by the clinic coordinator based on information from the patient’s completed intake form which included a medical history to screen out people who had great difficulty communicating in English and were unable to consent to the study. People were chosen for inclusion in the study using the criteria of being at least 18 years of age, without cognitive, vision or hearing impairment, and having either limited or no difficulty understanding the intake questions posed to the patient by the coordinator in English. Each eligible participant was given a letter describing the study, emphasizing the voluntary confidential nature of the research, and the subject’s ability to withdraw at any time, and inviting them to participate. This letter was read to the patient while they followed with their own copy in hand. Comprehension of the information was done by asking the subject to reiterate the procedures included in the study. Following informed consent, participants were administered the 84-item REALM-D and a 48-item survey instrument on health beliefs, attitudes, and knowledge. Each patient received $5.00 after completing the initial survey and another $5.00 after completing a follow-up survey.
The protocol for administration and scoring of the original instrument was retained. Each of the 200 study participants was given a laminated copy of the REALM-D by the interviewer and asked to read each word aloud. If the subject could not read a word, he/she was instructed to say “blank” and move to the next word. Over the course of the study, five interviewers were trained by the coinvestigator on how to administer and score the REALM-D instrument. Calibration was done by having two interviewers complete and score a sample REALM-D instrument as the coinvestigator listened for accurate phonetic pronunciation. Interviewers were given the original REALM-coding rubric and instructed to score accordingly, use the following marking system; a correctly pronounced word received a plus (+), a mispronounced word received check (√), and a word not attempted received a minus (−). Words pronounced correctly received a score of 1 by the interviewer, and mispronounced or not attempted words received a score of 0.
Atchison K.A., Gironda M.W., Messadi D, & Der-Martirosian C. (2010). Screening for oral health literacy in an urban dental clinic. Journal of public health dentistry, 70(4), 269-275.
Publication 2010
Adult Cognition Conditioning, Psychology Dental Health Services Diagnosis, Oral Ethics Committees, Research Health Literacy Hearing Impairment Interviewers Patients Treatment Protocols Vision
2
Retrospective Study on MDADI Scores in HNC
A retrospective cross-sectional study was conducted to identify clinically meaningful between-group differences in MDADI scores. HNC patients who completed MDADI questionnaires at the time of routine modified barium swallow (MBS) studies (03/2003-06/2011) were eligible for inclusion in the study. Inclusion criteria were: 1) diagnosis of oral cavity, oropharyngeal, nasopharyngeal, laryngeal, or thyroid cancer, and 2) complete MDADI scores recorded in the MDACC MBS Database. Nineteen hundred eighty-nine potentially eligible head and neck cancer patients with complete MDADI scores were identified by a search of the MDACC MBS tracking database. Eight hundred twenty-four patients were excluded according to the following criteria: more than 1 site of disease, metastatic disease, recurrent disease, patient <18 years of age at the time of MDADI, and those who underwent MBS in the early postsurgical period (within 6 weeks of surgery) when PO intake has not yet been attempted to allow appropriate completion the questionnaire. Therefore, 1,136 patients were included in this analysis. Institutional review board approval and a waiver of informed consent were obtained.
Hutcheson K.A., Portwood M., Lisec A., Barringer D.A., Gries K, & Lewin J.S. (2015). What is a Clinically Relevant Difference in MDADI Scores between Groups of Head and Neck Cancer Patients?. The Laryngoscope, 126(5), 1108-1113.
Publication 2015
Barium Cancer of Head and Neck Carcinoma, Thyroid Dental Caries Diagnosis Diagnosis, Oral Ethics Committees, Research Larynx Nasopharynx Neoplasm Metastasis Operative Surgical Procedures Oral Cavity Oropharynxs Patients
3
Oral Health Literacy Assessment in Dental Clinic
A secondary analysis of data collected from a sample of 200 adult patients seeking treatment for the first time from an Oral Diagnosis Clinic at a School of Dentistry in the United States between January 2005 and June 2006 were used for this study. In the original study, participants were screened by the clinic coordinator based on information from their completed intake form for inclusion in the study. Criteria included being at least 18 years of age, without cognitive, vision, or hearing impairment, and having at least limited understanding of English. Each eligible participant was given a letter describing the study and inviting them to participate, including information on receiving $5.00 after completing the initial survey and another $5.00 after completing a follow-up survey. Each of the 200 study participants was given a laminated copy of the 84-item REALM-D by the interviewer and asked to read each word aloud (16 (link)). The protocol for administration and scoring of the original instrument was retained and used for scoring the REALM-D. If the subject could not read a word, he/she was instructed to say “blank” and move to the next word. Interviewers were trained by the co-investigator on how to administer and score the REALM-D instrument. Words pronounced correctly received a score by the interviewer of 1 and mispronounced or not attempted words received a score of 0. Paper copies of a 48-item health beliefs and attitudes survey were also administered to the study subject. Categories of questions included patient health education assessment (UCLA clinic survey), health values, beliefs and attitudes, and health locus of control.
Gironda M., Der-Martirosian C., Messadi D., Holtzman J, & Atchison K. (2013). A brief 20-item dental/medical health literacy screen (REALMD-20). Journal of public health dentistry, 73(1), 50-55.
Publication 2013
Adult Cognition Diagnosis, Oral Educational Assessment Hearing Impairment Interviewers Patients Treatment Protocols Vision
4
Oral SCC in NPC Survivors: Survival Comparison
Medical records of consecutive patients with surgically treated primary oral SCC were reviewed between January 1985 to January 2019, enrolled patients must meet the following criteria: there was prior history of radiotherapy for NPC, and the latency between the diagnosis of oral SCC and the end of radiotherapy was not less than 3 years [13 (link),14 (link)]. Information regarding age, sex, operation record, treatment, and follow-up was collected and analyzed. All the pathologic sections were re-evaluated and patients were re-staged by the 7th edition American Joint Committee on Cancer classification.
To compare the survival between NPC survivors and sporadic oral SCC patients, patients with sporadic oral SCC were also reviewed during the same study period, each NPC survivor was matched with two sporadic oral SCC patients, the matching process was performed by age (±5 years), sex, primary tumor site, perineural invasion, lymphovascular invasion, smoker, disease stage (stage I/II vs. stage III/IV), neck node status (positive vs. negative), and tumor stage (T1/T2 vs. T3/T4) [11 (link)]. Perineural invasion was considered to be present if tumor cells were identified within the perineural space and/or nerve bundle, lymphovascular infiltration was positive if tumor was noted within the lymphovascular channels [15 (link)]. Drinkers were defined as those who consumed at least one alcoholic drink per day for at least 1 year [11 (link),16 (link)], smokers were defined as those smoked on a daily basis or had quit smoking for less than 5 years [11 (link)].
Dai L., Fang Q., Li P., Wu J, & Zhang X. (2019). Secondary Squamous Cell Carcinoma of the Oral Cavity after Nasopharyngeal Carcinoma. Cancer Research and Treatment : Official Journal of Korean Cancer Association, 52(1), 109-116.
Publication 2019
Alcoholics Cells Diagnosis, Oral Joints Neck Neoplasms Nervousness Patients Radiotherapy Survivors
5
Oral Anticoagulant Use in Atrial Fibrillation
We identified people with a first time purchase of a NOAC: apixaban (introduced 10 December 2012), dabigatran (1 August 2011), rivaroxaban (1 February 2012), as well as patients who started warfarin treatment (from 1 August 2011) up to 30 November 2015. All prescribed drugs in Denmark are partially reimbursed, based on a patient’s level of drug expenses.
To study a cohort of patients treated for atrial fibrillation, we applied several criteria. We restricted the consumption of NOACs to standard doses (apixaban 5 mg twice daily, dabigatran 150 mg twice daily, and rivaroxaban 20 mg once daily). Warfarin is only available in 2.5 mg dose tablets in Denmark. We decided to focus our analyses on patients receiving standard dosages of apixaban, dabigatran, and rivaroxaban, because patients who receive reduced dosage regimens have more comorbidities and are of more advanced age (>80 years). Thus, comparisons across various dosing regimens and choices of antithrombotic agent could result in comparisons on mixed cohorts in terms of comorbidities, age, and concomitant treatment. Confining the analysis to patients receiving standard dosages only will thus allow for easier interpretation and a more robust comparison of cohorts. To establish a cohort of patients who were naïve to oral anticoagulant treatment, we excluded those who had used any oral anticoagulant within one year. We also excluded patients with hospital diagnoses indicating valvular atrial fibrillation (mitral stenosis or mechanical heart valves) or venous thromboembolism (pulmonary embolism or deep vein thrombosis) to narrow the included patients to only those who were likely to have been prescribed oral anticoagulants because of a diagnosis of atrial fibrillation in either hospital or general practice. The entire cohort comprised patients with atrial fibrillation. We also analysed a subgroup of patients who had been admitted to hospital with a diagnosis of atrial fibrillation.
Larsen T.B., Skjøth F., Nielsen P.B., Kjældgaard J.N, & Lip G.Y. (2016). Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. The BMJ, 353, i3189.
Publication 2016
Administration, Oral Anticoagulants apixaban Atrial Fibrillation Dabigatran Deep Vein Thrombosis Diagnosis Diagnosis, Oral Fibrinolytic Agents Heart Valve Prosthesis Inpatient Mitral Valve Stenosis N(4)-oleylcytosine arabinoside Patients Pharmaceutical Preparations Pulmonary Embolism Rivaroxaban Treatment Protocols Venous Thromboembolism Warfarin

Most recents protocols related to «Diagnosis, Oral»

1
Cohort Study of HNSCC Patients in Croatia
All patients in this cohort study underwent surgery as primary treatment for HNSCC performed at the Department of Maxillofacial Surgery, Clinical Hospital Dubrava, University of Zagreb, Croatia, between 2015 and 2019 and followed-up until November 2022. Patients with a diagnosis of oral cancer (O; gingiva, retromolar area, oral tongue, sublingual area—excluding base of the tongue, buccal mucosa), as well as oropharyngeal cancer (OP; base of the tongue, tonsil, posterior pharyngeal wall) were included. In our previous study [33 (link)], a subset of patients was assessed by high-throughput methods for miRNA profiling. However, at that time, the patient follow-up was too short to make observations regarding outcomes. Within the current study, we collected follow-up information and included additional patients treated in the intervening period.
A total of 76 patients, 20 women (age range 32–87 years) and 56 men (age range 31–85 years), were included in the current study. Patients’ data from previously collected (n = 59) and newly enrolled patients (n = 17) are shown in Supplementary Table S1. For the current study additional detailed information including clinical tumour, node, and metastasis (cTNM) status, pathological TNM (pTNM) status, histological grade, presence of histopathologically assessed angioinvasion or perineural invasion or their combination, tumour involvement of surgical margins (and the distance to the margin), lymph node yield (LNY), positivity and ratio (LNR), presence of extranodal extension (ENE), postoperative treatments and survival information including disease recurrence (Table 1 and Table 2) were collected from hospital databases and medical records for all included patients. Tumours were staged by using the 8th edition of the AJCC Cancer Staging Manual [9 ]. Since p16 information was not available, cases were staged according to the p16 negative guidelines. Separate staging is shown for clinical and pathological TNM classification (Table 1 and Table 2). Furthermore, alcohol and tobacco consumption as risk factors were reviewed; however, pack/year or detailed alcohol consumption data were not available.
Informed consent was obtained from all patients, and the study (Epic-HNSCC project No 4758) was approved by the Clinical Hospital Dubrava Bioethics Committee (EP-KBD-10.06.2014) and the Ruđer Bošković Institute Bioethics Committee (BEP-3748/2-2014).
Šimić I., Božinović K., Milutin Gašperov N., Kordić M., Pešut E., Manojlović L., Grce M., Dediol E, & Sabol I. (2023). Head and Neck Cancer Patients’ Survival According to HPV Status, miRNA Profiling, and Tumour Features—A Cohort Study. International Journal of Molecular Sciences, 24(4), 3344.
Publication 2023
Cancer of Mouth Diagnosis Diagnosis, Oral Ethanol Extranodal Extension Gingiva Malignant Neoplasms MicroRNAs Mucosa, Mouth Neoplasm Metastasis Neoplasms Nodes, Lymph Operative Surgical Procedures Oropharyngeal Cancer Palatine Tonsil Patients Pharynx Recurrence Squamous Cell Carcinoma of the Head and Neck Surgical Margins Tongue Woman
2
Saliva-based Liquid Biopsy in HNSCC
This quantitative prospective cohort study was granted ethics approval from the Damascus University Human Ethics Committee (1065–2019) and was conducted in compliance with the principles of the Declaration of Helsinki and per the Reporting Recommendation for Tumor Marker Prognostic Studies (REMARK) [26 (link)]. Cases were selected from those accumulated by us between January 2019 and December 2020 for ongoing projects to assess the utility of saliva-based liquid biopsies in managing patients with HNSCC [19 (link)]. The cut-off day for the follow-up program was the end of January 2023. The overall survival of each patient was calculated from the date of diagnosis till (i) the time of death for deceased patients or (ii) the end of the project follow-up period for censored ones.
Cases were considered eligible for inclusion if they met the following criteria: (i) age of more than 18 years and signed informed consent, (ii) a confirmed microscopic diagnosis of either oral SCC or laryngeal SCC, (iii) no history of other malignancies, (iv) no history of receiving chemotherapy or radiotherapy, (v) no history of immunotherapy of immunodeficiency disorders, and (vi) the availability of complete follow-up data by the study cut-off day. The exclusion criteria were those with chronic systematic conditions, including pregnancy, and those who voluntarily decided to withdraw from the study.
Two senior pathologists blindly reviewed microscopic slides to confirm the diagnosis based on the World Health Organization (WHO) classifications [1 ]. The stage of HNSCC was determined as per the Eighth Edition American Joint Committee on Cancer staging Manual (TNM system) [7 (link)].
Sayal L., Hamadah O., AlMasri A., Idrees M., Kassem I., Habbal W., Alsalamah B, & Kujan O. (2023). Salivary-Based Cell-Free Mitochondrial DNA Level Is an Independent Prognostic Biomarker for Patients with Head and Neck Squamous Cell Carcinoma. Journal of Personalized Medicine, 13(2), 301.
Publication 2023
Chronic Condition Diagnosis Diagnosis, Oral Ethics Committees Homo sapiens Immunologic Deficiency Syndromes Immunotherapy Joints Larynx Liquid Biopsy Malignant Neoplasms Microscopy Pathologists Patients Pharmacotherapy Pregnancy Radiotherapy Saliva Squamous Cell Carcinoma of the Head and Neck Tumor Markers
3
Comprehensive Oral Frailty Assessment Protocol
A diagnosis of oral frailty was based on six criteria: (1) number of natural teeth; (2) chewing ability as an indicator of general masticatory performance; (3) maximum tongue pressure; (4) articulatory oral motor skill (“ta” sound); (5) subjective difficulties in eating hard foods; and (6) subjective difficulties in swallowing. We defined “oral non-frailty” as having no poor status for any of the above six criteria, while “oral frailty” was defined as having a poor status for three or more criteria [4 (link)].
“New-onset” oral frailty was defined as the first documentation of oral frailty since completion of the baseline survey. The follow-up period was defined as the number of years between the time of new-onset and completion of the baseline survey. On the other hand, “no-onset” oral frailty was defined as not meeting the criteria for oral frailty during the six-year follow-up period.
The number of natural teeth was assessed by dental professionals using the Zsig-mondy–Palmer system [12 (link)]. As almost all Japanese dental hygienists use this system, the inter-examiner calibration was deemed to be sufficient. Participants with less than 19 natural teeth were categorized as having a poor dental status [4 (link)].
Chewing ability was measured using a color-changing chewing gum (Xylitol; Lotte, Tokyo, Japan), which changes from green to red with chewing. Participants were asked to chew the gum for 60 s in the same way that they would chew food. We evaluated the gum’s redness using a colorimeter (Color Reader CR-13; Konica Minolta, Tokyo, Japan) [13 (link)]. Participants with the a-value (redness or greenness) of less than 14.2 (for men) or 10.8 (for women) were categorized as having a poor general masticatory performance [4 (link)].
Tongue pressure was measured with a hand-held balloon probe and manometer (JMS tongue pressure measurement instrument; GC, Tokyo, Japan) [14 (link)]. Participants were asked to place the balloon on the anterior part of their palate and to raise their tongue to compress the balloon onto the palate as forcefully as possible. Participants exerting a force of less than 27.4 kPa (for men) or 26.5 kPa (for women) were categorized as having a poor tongue pressure [4 (link)].
Oral diadochokinesis (“ta”) was assessed as a measure of articulatory oral motor skill [15 (link)]. Participants were asked to articulate this syllable repetitively as quickly as possible for five seconds. This syllable allowed for assessment of the three major articulatory organs: the lips, the tongue tip, and the tongue dorsum. Articulation counts were measured using a digital counter (T.K.K.3350 digital counter; Takei Scientific Instruments Co., Ltd., Niigata, Japan), and oral diadochokinesis was calculated separately, also using this syllable, as the articulation count per second. Participants with articulation rates of less than 5.2 times/second (for men) or 5.4 times/second (for women) were categorized as having poor articulatory oral motor skill [4 (link)].
Subjective assessments were conducted to evaluate difficulties in eating and swallowing, using the Kihon Checklist (KCL) questionnaire, an instrument designed to assess risk of dependence for older adults [16 ]. The checklist includes questions such as, “Do you have any difficulties eating hard foods compared to 6 months ago (Yes or No)?”; “Have you choked on your tea or soup recently (Yes or No)?”; and “Do you often experience having a dry mouth (Yes or No)?”
Nishimoto M., Tanaka T., Hirano H., Watanabe Y., Ohara Y., Shirobe M, & Iijima K. (2023). Severe Periodontitis Increases the Risk of Oral Frailty: A Six-Year Follow-Up Study from Kashiwa Cohort Study. Geriatrics, 8(1), 25.
Publication 2023
Aged ARID1A protein, human Chewing Dental Health Services Diagnosis, Oral Erythema Fingers Food Gums, Chewing Hygienist, Dental Japanese Joints Lip Manometry Motor Skills Palate Pressure Sound Tongue Woman Xerostomia Xylitol
4
White Asymptomatic Oral Lesions Study
Four male patients, aged 14, 19, 22 and 37 respectively, were referred to the Dental Clinic of Fondazione Policlinico Gemelli (FPG), Catholic University of Rome, for the diagnosis of white asymptomatic diffuse oral lesions. They were all selected for this study, because the aspect of the lesions led to the suspicion of WSN; given its rarity, the number of patients was considered sufficient for this observational study. The study was approved by the Ethic Committee of the Università Cattolica del Sacro Cuore (#565). A written consent, including information about the diagnostic procedures i.e., oral biopsy, exfoliative cytology and genetic testing, was given to all patients, and to the parents of the minor.
Lajolo C., Cafiero C., Stigliano E., Grippaudo F.R., Chiurazzi P, & Grippaudo C. (2023). Exfoliative Cytology and Genetic Analysis for a Non-Invasive Approach to the Diagnosis of White Sponge Nevus: Case Series. Bioengineering, 10(2), 154.
Publication 2023
Biopsy Cytological Techniques Diagnosis Diagnosis, Oral Ethics Committees Males Parent Patients Roman Catholics Tests, Diagnostic Tooth Exfoliation
5
Erosive and Atrophic Oral Lichen Planus Protocol
Patients were recruited from the out-patient clinic, the Department of Oral Medicine, Oral Diagnosis and Periodontology, Faculty of Dentistry, Ain Shams University, and Faculty of Oral and Dental Medicine, Future University.
Both genders between the ages of 25 and 60 years old, systemically free based on a structured medical questionnaire, and with clinically and histologically confirmed painful erosive or atrophic OLP according to the American Academy of oral and maxillofacial pathology [18 (link)] and a minimum clinical score of 2 were included. The exclusion criteria included; pregnancy, breast-feeding, smoking, history of drug-induced lichenoid lesions, loss of pliability or flexibility in the tissues involved by the oral lesions of lichen planus, potential treatment of OLP for less than 2 weeks by topical and 4 weeks’ systemic therapy before study, and known hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation [16 (link)].
Ibrahim S.S., Ragy N.I., Nagy N.A., El-kammar H., Elbakry A.M, & Ezzatt O.M. (2023). Evaluation of muco-adhesive tacrolimus patch on caspase-3 induced apoptosis in oral lichen planus: a randomized clinical trial. BMC Oral Health, 23, 99.
Publication 2023
Atrophy Diagnosis, Oral Drug Reaction, Adverse Faculty Gender Hypersensitivity Lichen Planus, Oral Lichens Outpatients Pain Patients Pharmaceutical Preparations Pharmaceutical Preparations, Dental Pregnancy salicylhydroxamic acid Tissues

Top products related to «Diagnosis, Oral»

1
Spss statistics for windows version 17 by IBM
Sourced in United States
SPSS Statistics for Windows, Version 17.0 is a software product for statistical analysis. It provides tools for data management, analysis, and presentation.
2
Marketscan database by IBM
MarketScan database is a comprehensive database that contains de-identified, individual-level healthcare claims data from private and public payers. The database includes information on medical and pharmacy claims, lab results, and enrollment data from a large sample of individuals covered by employer-sponsored private health insurance plans.
3
Stata 14 by StataCorp
Sourced in United States, Denmark, United Kingdom, Belgium, Japan, Austria, China
Stata 14 is a comprehensive statistical software package that provides a wide range of data analysis and management tools. It is designed to help users organize, analyze, and visualize data effectively. Stata 14 offers a user-friendly interface, advanced statistical methods, and powerful programming capabilities.
4
Purelink genomic dna kit by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, Italy, Brazil
The PureLink Genomic DNA Kit is a laboratory equipment product designed for the rapid and efficient extraction and purification of genomic DNA from a variety of sample types. It utilizes a spin column-based method to isolate high-quality DNA that can be used in various downstream applications.
5
Spss software version 18 by IBM
Sourced in United States, United Kingdom, China
SPSS software version 18.0 is a statistical analysis software package developed by IBM. It provides tools for data management, analysis, and presentation. The software is designed to assist users in managing, analyzing, and visualizing data effectively.
6
Collagenase type 1 solution by Thermo Fisher Scientific
Sourced in United States
Collagenase type I solution is a laboratory reagent used for the digestion and dissociation of collagen-rich tissues. It contains a purified enzyme that breaks down the collagen matrix, allowing for the isolation and extraction of cells from the tissue.
7
Eclipse 80i microscope by Nikon
Sourced in Japan, United States, France, Germany, China, Canada, United Kingdom, Netherlands
The Eclipse 80i microscope is a high-performance optical microscope designed for a variety of scientific applications. It features a sturdy and ergonomic design, advanced optical components, and a range of accessories to accommodate diverse research needs. The Eclipse 80i provides clear, high-resolution imaging capabilities to support laboratory tasks.
8
Pcp unc 15 by Hu-Friedy
Sourced in United States, Germany
The PCP-UNC 15 is a dental lab instrument designed for ultrasonic scaling and root debridement procedures. It features a slim, angled design and a standard UNC 15 tip size for clinical versatility.
9
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.

More about "Diagnosis, Oral"

Oral diagnosis, also known as oral assessment or dental diagnosis, is the process of identifying and evaluating conditions affecting the mouth, teeth, and associated structures.
This field encompasses a range of techniques and technologies, including SPSS Statistics for Windows, Version 17.0, and Stata 14, to assess oral health, detect abnormalities, and guide treatment decisions.
Accurate oral diagnosis is crucial for maintaining optimal oral function, preventing complications, and improving patient outcomes.
Key subtopics in oral diagnosis include the use of the PureLink Genomic DNA Kit, Collagenase type I solution, and the Eclipse 80i microscope to analyze tissue samples, as well as the application of PCP-UNC 15 and Penicillin/streptomycin in diagnostic procedures.
The MarketScan database and SPSS software version 18.0 can be utilized for data analysis and research in this field.
PubCompare.ai revolutionizes oral diagnosis research by helping users locate the best protocols from literature, pre-prints, and patents.
Its AI-driven comparisons identify the optimum protocols and products, streamlining your research reproducibility and taking your oral diagnosis studies to new highs.
Explore PubCompare.ai today and elevate your oral diagnosis research to new heights.